Format

Send to

Choose Destination
See comment in PubMed Commons below
Lancet Oncol. 2013 Oct;14(11):e438. doi: 10.1016/S1470-2045(13)70412-1.

Intercalated chemotherapy and erlotinib: a viable first-line option for patients with advanced NSCLC?

Author information

1
Department of Medical Oncology, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, 79 Qingchun Road, Hangzhou, Zhejiang, 310003, China.
PMID:
24079869
DOI:
10.1016/S1470-2045(13)70412-1
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center